Want to join the conversation?
For 2016, $LH expects net revenue to grow in the range of 7.5-9.5% vs. 2015 net revenue of $8.51Bil, including the impact from approx. 100 BP of negative currency. 2016 net revenue is expected to grow between 3.5-5.5% in LabCorp Diagnostics and 2-5% in Covance Drug Development. Adjusted EPS is expected to be $8.45-8.85, up approx. 7-12% for 2016.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?